Login to Your Account



BIO 2011 International Convention

Biosimilar IP Strategies Call for Intricate Choreography

By Mari Serebrov


Wednesday, June 29, 2011
WASHINGTON – Compared with the abbreviated new drug process, the biosimilar pathway looks like an intricately choreographed dance of notification, disclosure and negotiations between the innovator and the follow-on.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription